<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190404043159N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-08</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Impact of educational programs, self-hypnosis, and web-based bioenergy economics on patients with irritable bowel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the impact of educational programs, self-hypnosis, and web-based bioenergy economics on the severity of symptoms, awareness, quality of life anxiety and depression in patients with irritable bowel syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>120</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74562</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Factorial, Purpose: Treatment, Randomization description: In this study randomization performs based on the blocked randomization method. Information such as the number of study groups (3 main groups: 2 intervention groups (for example A,B) and a control group (for example (C), block size (a multiple of the number of groups that will be chosen in this study to reduce the complexity of the work, size 4) and the total number of patients (sample size 120 people), were enter into the online software machines specific for this calculation (for example available at https://www.sealedenvelope.com/simple-randomiser/v1/lists) and according to the codes that it is obtained by the final analysis (for example (group B 1, 4, 1), each of the patients being studied is given a specific code respectively. Blocking is usually used in order to create a balance in the number of samples assigned to each of the studied groups. In this method, equal blocking will be used. In this way, the samples are randomized in two groups as much as possible, Blinding description: One researcher performs randomization of individuals into three groups and then sets up the receipt of web-based programs. The second researcher, who is unaware of the group assignments, evaluates patients using the questionnaires.</study_design>
      <phase>3</phase>
      <hc_freetext>Irritable bowel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: in addition to basic training, simultaneously undergoes Gut-Directed Hypnotherapy training, through audio files. These audio files include self-hypnosis training, which are recorded by the hypnotherapist and patients practice them at home between weekly sessions. According to the standard, the hypnotherapy process includes the following stages: induction, relaxation, deepening, therapeutic suggestions focused on the GI system, ego strengthening and emergence. Intervention 2: Second intervention group: apart from basic training, also receives weekly training on bio-energy economics for IBS, using audio files and brochures.These part include mental and behavioral, and motor techniques that reduce psychosomatic symptoms by regulating body movements and ergonomics and proportional distribution of biological energy. The 6-week IBS program is the abbreviated form of this program, which includes four sections relating to the body, thoughts, others, and existence. Intervention 3: Control group: undergo a 6-weeks basic training on various aspects of Irritable Bowel Syndrome (IBS) such as disease definition, signs and symptoms, diagnosis, lab tests, medical and non medical treatments, and prognosis.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can be shared after people have requested.

When:
Six months after publishing the results

To whom:
Academic researchers

Conditions:
Scientific uses

Where to obtain:
Isfahan University of Medical Sciences website

How to obtain:
Clear request on the site to access the data by the individual and then review the request by the research assistant within 2 weeks and then allow access to the data

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Reza Sharbafchi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 22, Roshd Ave., Daneshgah Blvd., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 0042</telephone>
        <email>sharbafchi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Reza Sharbafchi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 22, Roshd Ave., Daneshgah Blvd., Isfahan</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 0042</telephone>
        <email>sharbafchi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Both male and female participants aged 18 to 65 years
Diagnosis of moderate to severe IBS based on ROME III criteria and exclusion of potential organic causes by gastroenterology specialists
Basic literacy skills (reading and writing)
Ability to work with and access software applications
Satisfaction to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diagnosis of any organic disease during the study period that renders continued participation impossible
Diagnosis of depression disorders, bipolar disorders, or psychotic disorders based on DSM-V diagnostic criterias assessed by a psychiatrist and psychiatric assistant
Serious suicidal thoughts or plans at the time of study entry
Use of antidepressant or antianxiety medications within 2 weeks prior to study entry
Participation in psychotherapeutic programs within 2 months prior to study entry
Pregnant or breastfeeding
History of bowel surgery
Substance abuse since the onset of symptoms</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K58</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Irritable bowel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: in addition to basic training, simultaneously undergoes Gut-Directed Hypnotherapy training, through audio files. These audio files include self-hypnosis training, which are recorded by the hypnotherapist and patients practice them at home between weekly sessions. According to the standard, the hypnotherapy process includes the following stages: induction, relaxation, deepening, therapeutic suggestions focused on the GI system, ego strengthening and emergence.</i_keyword>
      <i_keyword>Second intervention group: apart from basic training, also receives weekly training on bio-energy economics for IBS, using audio files and brochures.These part include mental and behavioral, and motor techniques that reduce psychosomatic symptoms by regulating body movements and ergonomics and proportional distribution of biological energy. The 6-week IBS program is the abbreviated form of this program, which includes four sections relating to the body, thoughts, others, and existence.</i_keyword>
      <i_keyword>Control group: undergo a 6-weeks basic training on various aspects of Irritable Bowel Syndrome (IBS) such as disease definition, signs and symptoms, diagnosis, lab tests, medical and non medical treatments, and prognosis.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of Irritable Bowel Syndrome symptoms. Timepoint: Before and after 6 weeks training. Method of measurement: The irritable bowel severity scoring system (IBSSS).</prim_outcome>
      <prim_outcome>Depression. Timepoint: Before and after 6 weeks training. Method of measurement: Hospital Anxiety and Depression Scale (HADS).</prim_outcome>
      <prim_outcome>Anxiety. Timepoint: Before and after 6 weeks training. Method of measurement: Hospital Anxiety and Depression Scale (HADS).</prim_outcome>
      <prim_outcome>Quality of life. Timepoint: Before and after 6 weeks training. Method of measurement: Irritable Bowel Syndrome Quality of Life (IBS-QOL-34).</prim_outcome>
      <prim_outcome>Awareness level. Timepoint: Before and after 6 weeks training. Method of measurement: Which number from 0 to 100 rates your awareness level of your disease?.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-15</approval_date>
        <contact_name>Ethics committee of Esfahan university of Medical sciences</contact_name>
        <contact_address>No. 18, Hezar Jarib Ave., Daneshgah Blvd., Isfahan Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
